Trial · NCT00660179
Results by group108
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 108
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | Placebo | Kaplan-Meier estimate at Month 6 | 80.1 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 3 mg | Kaplan-Meier estimate at Month 6 | 89.3 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 10 mg | Kaplan-Meier estimate at Month 6 | 92.7 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | Placebo | Kaplan-Meier estimate at Month 12 | 71.4 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 3 mg | Kaplan-Meier estimate at Month 12 | 81.6 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 10 mg | Kaplan-Meier estimate at Month 12 | 85.5 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | Placebo | Kaplan-Meier estimate at Month 18 | 61.5 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 3 mg | Kaplan-Meier estimate at Month 18 | 72.5 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 10 mg | Kaplan-Meier estimate at Month 18 | 79.9 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | Placebo | Kaplan-Meier estimate at Month 24 | 57.3 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 3 mg | Kaplan-Meier estimate at Month 24 | 65.5 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 10 mg | Kaplan-Meier estimate at Month 24 | 74.3 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | Placebo | Kaplan-Meier estimate at Month 30 | 50.2 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 3 mg | Kaplan-Meier estimate at Month 30 | 61.9 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 10 mg | Kaplan-Meier estimate at Month 30 | 70.0 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | Placebo | Kaplan-Meier estimate at Month 36 | 47.0 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 3 mg | Kaplan-Meier estimate at Month 36 | 55.0 | percentage of participants-Kaplan Meier | |
| Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event) | ACT-064992 10 mg | Kaplan-Meier estimate at Month 36 | 63.2 | percentage of participants-Kaplan Meier | |
| Time to Death Due to PAH or Hospitalisation for PAH up to the End of Treatment (Kaplan-Meier Estimate of Patients Without an Event) | Placebo | Kaplan-Meier Estimate at Month 6 | 84.8 | percentage of participants-Kaplan Meier | |
| Time to Death Due to PAH or Hospitalisation for PAH up to the End of Treatment (Kaplan-Meier Estimate of Patients Without an Event) | ACT-064992 3 mg | Kaplan-Meier Estimate at Month 6 | 90.8 | percentage of participants-Kaplan Meier |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00660179/results